BioSpace News Archive

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the grant of Chinese Patent Number 106414487 B covering OPT-302, its soluble VEGFR-3 “trap” molecule currently being investigated in two global Phase 3 registrational clinical trials, ShORE and COAST.

Diverse Biotech, Inc. announced that its DBT-12733 molecule was more effective in killing glioblastoma tumor cells than temozolomide, outperforming all expectations in early testing.

Cambrian Biopharma, a multi-asset longevity biotech, announced the close of an oversubscribed Series C financing, which raised $100 million.

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, for the reimbursement of Trogarzo® for eligible people aged 18 and older living with multi-drug resistant HIV-1.

Ulcerative colitis is a chronic idiopathic inflammatory bowel disease of the gastrointestinal tract that affects the mucosal lining of the colon.

Lupus nephritis refers to the kidney damage caused by the disease lupus erythematosus. Lupus erythematosus is an autoimmune disease where the immune system turns against the body, affecting vital organs.

Globally, the adoption of exosome diagnostics and therapeutics market is anticipated to witness a significant boost with the growing focus on life science research and increasing diagnostic procedures for cancer.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global blood cancer diagnostics market is expected to grow by 6% CAGR during the forecast period of 2021 to 2031.

BioSpace, the leader in biopharma news and careers released a report that found 80% of unvaccinated respondents would resign if their employer required them to get the COVID-19 vaccine.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has been named by the Orange County Business Journal as the fastest growing publicly traded company in Orange County.